China’s NMPA approves Novartis’ Cosentyx for psoriasis

Novartis said China's National Medical Products Administration approved Cosentyx secukinumab to treat moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Cosentyx was included on China’s first batch of urgently needed drugs approved overseas and eligible for Priority Review. The list was drafted last year to accelerate approval of drugs with "significant clinical value" (see "China Releases List of Overseas Drugs Eligible for Priority Review")...